Related Experiment Video
Updated: Sep 29, 2025
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
Targeting CDK4 and CDK6 in cancer
Shom Goel1,2, Johann S Bergholz3,4,5, Jean J Zhao6,7,8
1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. shom.goel@petermac.org.
Abstract:
Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular transition into S phase and are important for the initiation, growth and survival of many cancer types. Pharmacological inhibitors of CDK4/6 have rapidly become a new standard of care for patients with advanced hormone receptor-positive breast cancer. As expected, CDK4/6 inhibitors arrest sensitive tumour cells in the G1 phase of the cell cycle. However, the effects of CDK4/6 inhibition are far more wide-reaching. New insights into their mechanisms of action have triggered identification of new therapeutic opportunities, including the development of novel combination regimens, expanded application to a broader range of cancers and use as supportive care to ameliorate the toxic effects of other therapies. Exploring these new opportunities in the clinic is an urgent priority, which in many cases has not been adequately addressed. Here, we provide a framework for conceptualizing the activity of CDK4/6 inhibitors in cancer and explain how this framework might shape the future clinical development of these agents. We also discuss the biological underpinnings of CDK4/6 inhibitor resistance, an increasingly common challenge in clinical oncology.
Insights
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are vital cancer treatments that halt cell cycle progression. Emerging research reveals broader applications and challenges like resistance, necessitating further clinical investigation.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Cyclin-dependent kinase 4 (CDK4) and CDK6 are crucial for cell cycle progression into S phase.
- CDK4/6 inhibitors are established treatments for advanced hormone receptor-positive breast cancer, inducing G1 cell cycle arrest.
Purpose of the Study:
- To provide a framework for understanding CDK4/6 inhibitor activity in cancer.
- To explore new therapeutic opportunities, combination regimens, and expanded cancer applications.
- To discuss mechanisms of CDK4/6 inhibitor resistance and future clinical development.
Main Methods:
- Review of current literature on CDK4/6 inhibitors.
- Analysis of emerging mechanisms of action beyond cell cycle arrest.
- Discussion of clinical trial data and resistance pathways.
Main Results:
- CDK4/6 inhibitors have effects beyond G1 arrest, suggesting wider therapeutic potential.
- New insights identify opportunities for novel combination therapies and expanded cancer indications.
- Understanding resistance mechanisms is critical for optimizing treatment strategies.
Conclusions:
- CDK4/6 inhibitors offer significant therapeutic benefits but face challenges like resistance.
- Further clinical exploration is urgently needed to realize the full potential of these agents.
- A conceptual framework can guide future development and application of CDK4/6 inhibitors in oncology.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39Positive Regulator Molecules
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...